SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane

BACKGROUND: HER2-positive breast cancer is usually associated to the more aggressive progression and the worse prognosis, but the mechanism underlying the innate resistance to HER2-targeted therapy remains elusive. The scaffold protein SH3-domain-binding glutamic acid-rich protein-like protein (SH3B...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Li, Hui, Zhang, Mingming, Wei, Yanli, Haider, Farhan, Lin, Yitong, Guan, Wen, Liu, Yanbin, Zhang, Shaoyang, Yuan, Ronghua, Yang, Xia, Yang, Shulan, Wang, Haihe
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7204297/
https://ncbi.nlm.nih.gov/pubmed/32381043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-020-01577-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados